3.6 Safety outcomes
Bleeding complications occurred in 11.7% (n= 54) of all patients (table
4). Patients who had a bleeding at admission were more likely to be
those who were already using a combined antithrombotic therapy prior to
admission, whereas bleeding during hospitalisation was more likely to
occur among patients who started the combined antithrombotic therapy
during hospitalisation. Although the total of
patients are small per subgroup, the overall bleeding rate seems to be
the highest in the subgroup of patients who were using TAT prior to
hospitalisation.
The overall rate of thromboembolism in this study population was 5.4%
(n=25) (table 4). This rate seems to be higher among patients at
admission who therefore initiated a combined antithrombotic therapy
during hospitalisation. However, two patients (2.1%) still had a
thromboembolism at admission despite that DAT was initiated prior to
hospitalization. A thromboembolism during hospitalization was seen in
1.3% (n= 6) of all patients and these patients all had initiated their
combined therapy (DAT) after the thromboembolism.
The overall mortality rate was 4.3% (table 4).